5). These data illustrated that Hystem-C? as a delivery vehicle could in fact improve both short-term retention and long-term engraftment of CDCs in http://www.selleckchem.com/products/Imatinib(STI571).html the setting of MI, and could also lead to improvements in treatment efficacy as assessed by cardiac function and cell activity in vivo. These data in total serve as compelling proof-of-concept for the CDC-hydrogel combination therapy. Figure 3. Enhanced cell engraftment by delivering CDCs in Hystem-CTM. (A and B) Representative confocal images showing engraftment of DiI-labeled human CDCs (red) 24 h after injection into post-MI mouse hearts. (C) Quantitative PCR analysis of … Figure 4. Cardiac function and heart morphometry. (A) Changes of left ventricular ejection fraction (LVEF) measured by echocardiography from baseline to 3 weeks in each group.
(B) Quantitative analysis and LV morphometric parameters of Masson��s … Figure 5. Promotion of angiogenesis by CDC/hydrogel transplantation. (A) Representative confocal images showing �� smooth muscle actin-positive vasculature in the hearts receiving various treatment products. (B) Quantitation of �� … Advancing a Cardiosphere-Derived Cell and Hydrogel Combination Therapy to the Clinic Next steps for the CDC-hydrogel combination therapy will include compatibility testing with one of several catheter-based transendocardial injection systems and large animal studies to evaluate safety and efficacy in a clinically-relevant model. An appropriate patient population, perhaps one in which intracoronary infusion in a previously infarcted artery poses a safety risk, can then be targeted for a first clinical study.
In the arena of cell therapy for MI, a new product that can overcome the widespread issues affecting cell engraftment should ultimately result in greater clinical benefits for patients. Cardiosphere-derived cells paired with Hystem-C? have shown great promise thus far in preclinical testing. Such a product may also reduce the manufacturing time and cost needed to generate an adequate therapeutic dosage, making the therapy more accessible to patients. The general techniques developed and knowledge gained from this study may be applicable to other cell types as well,32 and delivery with Hystem-C? may in fact benefit the field of cell therapy for MI as a whole. Footnotes Previously published online: www.landesbioscience.
Monoclonal antibodies (mAbs) have revolutionized the field of biology and medicine since their first description in 1975.1 However, AV-951 the development of therapeutic monoclonal antibodies has been complicated by a number of technical challenges including the appearance of immunogenic responses against murine antibody domains, and their inability to trigger human effector functions.2 These drawbacks were overcome initially by the generation of chimeric and humanized antibodies and now can be completely avoided by using fully human antibodies.